Get a free sample of Sirolimus Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Sirolimus Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Sirolimus Market Size
Sirolimus Market size was valued at around USD 270.7 million in and is anticipated to register a CAGR of 3.6% between 2024 and 2032. Sirolimus is a medication classified as an immunosuppressant and mammalian target of rapamycin (mTOR) inhibitor. Originally developed as an antifungal agent sirolimus is primarily used in transplantation medicine to prevent organ rejection in patients receiving kidney, liver, or heart transplants. It works by inhibiting the activity of the mTOR protein kinase, plays a crucial role in cell growth and proliferation.
The increasing prevalence of organ transplants is a significant driver for the market. For instance, according to the Health Resources and Services Administration, in 2023, the U.S. witnessed 15,927 kidney transplants, 6,413 liver transplants, 67 pancreas transplants, 2,671 heart transplants, 1,778 lung transplants, and 93 other types of transplants. Thus, the growing demand for organ transplants is fueling the expansion of the market for organ transplantation-related products and services, including immunosuppressant medications.
Furthermore, market growth is attributed to multiple factors, including the promising pipeline for different indications, advancements in pharmaceutical drug delivery systems, and rapid advancements in healthcare infrastructure.
Who are the key leaders in the sirolimus industry?
Apotex Inc., Concord Biotech, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Livzon Pharmaceuticals Group Inc., Pfizer Inc., Tiefenbacher API + Ingredients GmbH & Co. KG, Torrent Pharmaceuticals Ltd., and Zydus Group, are some of the major sirolimus companies worldwide.
What is the size of the North America sirolimus market?
North America sirolimus industry exceeded 109.7 million in 2023 due to the presence of state-of-the-art medical facilities, research institutions, and pharmaceutical companies in the region.
Why is the use of sirolimus in organ transplant rejection growing?
The organ transplant rejection segment recorded USD 120.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its immunosuppressive properties and anti-proliferative effects on vascular smooth muscle cells.
How big is the sirolimus industry?
Sirolimus market size crossed USD 270.7 million in 2023 and is expected to reach over USD 370.4 million by 2032 owing to the increasing prevalence of organ transplants and promising pipeline for different indications worldwide.